The conundrum It shouldn’t, but it always surprises me when the sp reacts to results which are exactly ‘as expected’. I suspect that the potential success of MED conflicts directly with the CSD sales - so why pay a premium for a product where the market will potentially decrease once MED released into the wider public, especially if over the counter. Still, I would suspect that a market for it would still exist… just needs some clever negotiating from a company wishing to licence. It’s a shame to see all the hard work and patience over the years wasted. Equally it is probably not in FUM’s interest when trying g to licence out MED and negotiating prices etc to have one of their own products in competition - and I would be surprised if the potential suitors haven’t said exactly that.
The conundrum Recruitment on track and absolutely flying by the looks of it!
The conundrum On the contrary JB was very upbeat on a deal being struck and we all know where that ended up. My point being this… that coming across confident or not is meaningless I have found. What does matter is the phase 3 trials are an absolute hit, and given the safety data so far it looks very promising! If we can get the 0.6 percent dose through these trials without any serious adverse effects it could form the basis for our high dose and perhaps the 0.4 percent as the lower dose. Come on FUM!! Let’s bring happiness to the faces of men and women all over the world!!!
The conundrum I personally thought he wasn’t very upbeat… though all hes doing is repeating the same old stuff which is boring now. He also looks alarming grey suddenly? maybe the stress of it all is taking it toll…
The conundrum Did you see how crazy that tie was …JB is clearly on a final path of confidence!!! Starting next September we will see the share price climbing towards december when numbers will be revealed…however, not sure TPR will get an approval by the end of Q2, more likely end Q3 or even Q4
The conundrum Completely agree Aberdeen. The long wait is nearing closure (one way or another). No doubt there will be some swings along the way, but what else is new? Feeling confident in the end game on this one. GLA, See you all at the BA lounge, cigars and beers at the ready!
The conundrum Yes I agree. It’s a long and winding road!
The conundrum I think it’s oretty safe to say it all really does boil down to the phase 3 trials. So come on board if you are happy to wait till December. I suspect more people will start to jump onboard as the headline results date approaches. Until then not much to really discuss on this one. Gone are the days of conspiracy theories! Good luck all! We will come out of this financially better off !!
The conundrum Underwhelmed by the results, especially the explanatory comments. “Viagra in a condom” appears to have shot its bolt while pain relief is still jam tomorrow. Unimpressed, as is the market
The conundrum She might even let him pick which Ralph Lauren shirt he wears, if he’s lucky
The conundrum Could well be, this drop was significant it seems. Oh well, tomorrow will be a good day, I heard that JB’s wife now decides which tie he is allowed to wear…and he feels just fine cause he knows the foundation for a billion deal is imminent…
The conundrum I can’t help but feel today’s drop was linked to N4P. Quite a few speculators put money in both FUM and N4P and today’s sudden drop in N4P May have led some to sell here to “average down” in N4P. Offcourse I’m only speculating!
The conundrum SENIOR DEVELOPMENT SCIENTIST / TEAM LEADER (FORMULATION) We are currently have a vacancy for someone to join our product development team. This is an exciting opportunity to be part of an ambitious, fast-growing pharmaceutical company whose success is built on quality, consumer focus and an innovative mind set. The role is varied but you will focus primarily on product formulation and development of new and existing pharmaceutical, medical device and cosmetic products across a diverse product range, including gels, creams, ointments, solutions and suspensions. Managing a small team of experienced staff we are looking for highly motivated applicants who can work well both in a team and individually. Essential Skills / Experience • Relevant scientific degree qualification • Previous experience in an R&D environment • Knowledge of the requirements for formulation development in the pharmaceutical, medical device or cosmetic industry • A positive attitude and a willingness to get the job done • Clear verbal and written communication skills • Excellent problem solving abilities
The conundrum [link]
The conundrum To pour cold water on my own hunch, Stadas 2018 annual rep highlights 750 MMAs. Looks like they had 700 approvals.